This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Gilead Proves Again Why It's the Best Biotech Company on the Planet

Gilead's hepatitis C drugs are probably the best example of the innovation in medicine we want the biotech industry to strive for when developing new products.

Amgen Wins Approval for Cancer-Killing Virus Drug

Amgen will market the new drug under the brand name Imlygic. Last Friday, Imlygic also won support from a committee of European drug reviewers.

Merck Talks Cancer, Cholesterol and Hepatitis Drugs on Quarterly Call

Merck will conduct an interim analysis before the end of the year of a large, phase III study investigating its cholesterol-lowering pill anacetrapib.

BioBlast Scant Data Links Drug to Improved Swallowing in Patients

BioBlast paints a very optimistic picture of Cabaletta's potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.

Valeant Defends Business Practices, Investors Take Sides

Two Valeant investors, one long, the other short, offer their views for what happens to the stock in the months ahead.

Why Valeant Isn’t Enron -- or Like Any Other Drug Stock

Whether the allegations against Valeant are true or not, they shouldn't be tainting most other biotech and drug stocks. That's because Valeant is in its own unique universe.

Abbvie Hep C Drug Safety Warning Prompts Panic Selling, Totally Unjustified

Investors are totally overreacting to what might be a small hit to Abbvie's hepatitis C revenue.

Northwest Bio Bothers British Bestie for Bounteous Bucks

British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.

Biogen Banks on High-Risk Drugs to Recapture Biotech Buzz

Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.

Biogen to Cut 11% of Workforce, Multiple Sclerosis Drugs Sales Improve

The company raised earnings and revenue guidance modestly for the remainder of the year due to the cost savings from the restructuring.

Page 3 of 346
Top Rated Stocks Top Rated Funds Top Rated ETFs